Stockscreener 앱 받기
4.15
5.62%
-0.21
전일 마감가:
$4.36
열려 있는:
$4.41
하루 거래량:
793.11K
Relative Volume:
0.32
시가총액:
$355.63M
수익:
-
순이익/손실:
$-36.95M
주가수익비율:
-4.9405
EPS:
-0.84
순현금흐름:
$-33.46M
1주 성능:
-14.45%
1개월 성능:
+4.71%
6개월 성능:
+127.35%
1년 성능:
-41.13%
1일 변동 폭
$4.10
$4.41
1주일 범위
$4.10
$4.99
52주 변동 폭
$1.61
$9.50
Larimar Therapeutics Inc Stock (LRMR) Company Profile
명칭
Larimar Therapeutics Inc
전화
844-511-9056
주소
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
LRMR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.155 | 373.17M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.20 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.85 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.46 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
807.98 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.21 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 개시 | Truist | Buy |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-10-03 | 개시 | Wedbush | Outperform |
| 2024-10-02 | 개시 | H.C. Wainwright | Buy |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-04-03 | 개시 | Leerink Partners | Outperform |
| 2023-11-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-19 | 개시 | Guggenheim | Buy |
| 2022-02-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 개시 | JMP Securities | Mkt Outperform |
| 2021-02-01 | 개시 | William Blair | Outperform |
모두보기
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
Real time breakdown of Larimar Therapeutics Inc. stock performanceQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Multi factor analysis applied to Larimar Therapeutics Inc.Market Volume Report & Capital Efficient Trade Techniques - newser.com
Is Larimar Therapeutics Inc. stock poised for growth2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
Larimar Therapeutics (NASDAQ:LRMR) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Intraday pattern recognizer results for Larimar Therapeutics Inc.2025 Buyback Activity & Consistent Profit Focused Trading Strategies - newser.com
How to forecast Larimar Therapeutics Inc. trends using time seriesQuarterly Profit Review & Stock Portfolio Risk Control - newser.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Volatility clustering patterns for Larimar Therapeutics Inc.July 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - newser.com
What MACD and RSI say about Larimar Therapeutics Inc.Trade Ideas & Verified Stock Trade Ideas - newser.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How Larimar Therapeutics Inc. (ZA71) stock compares with top peersMarket Trend Review & High Conviction Buy Zone Alerts - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
Larimar announces 25 mg, 50 mg data from OL study of nomlabofusp - MSN
Citizens JMP Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
Why Larimar Therapeutics Inc. (ZA71) stock fits value portfoliosDip Buying & Short-Term Trading Alerts - newser.com
Using Python tools to backtest Larimar Therapeutics Inc. strategiesJuly 2025 Pullbacks & Risk Adjusted Buy/Sell Alerts - newser.com
Can you recover from losses in Larimar Therapeutics Inc.2025 Price Momentum & Risk Controlled Stock Alerts - newser.com
Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia - MyChesCo
What’s next for Larimar Therapeutics Inc. stock priceEarnings Overview Report & Accurate Technical Buy Alerts - newser.com
Market reaction to Larimar Therapeutics Inc.’s recent newsWeekly Trend Report & Proven Capital Preservation Tips - newser.com
What analysts say about Larimar Therapeutics Inc stockDouble Top/Bottom Patterns & Low Risk Trading Portfolio - earlytimes.in
Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? - Yahoo Finance
Why Larimar Therapeutics (LRMR) Is Up After Positive Long-Term Results for Friedreich's Ataxia Therapy - Sahm
Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $21.00 by Analysts at Oppenheimer - Defense World
Why ETFs are accumulating Larimar Therapeutics Inc. (ZA71) stockDividend Hike & Real-Time Stock Movement Alerts - newser.com
Is Larimar Therapeutics Inc. (ZA71) stock worth buying before Fed actionJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Oppenheimer Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Oppenheimer Lowers Larimar Therapeutics (LRMR) Price Target to $21 | LRMR Stock News - GuruFocus
Equities Analysts Issue Forecasts for LRMR FY2027 Earnings - MarketBeat
Is now a turning point for Larimar Therapeutics Inc.2025 Technical Overview & High Accuracy Trade Alerts - newser.com
What analysts say about CTVA stockCandlestick Pattern Analysis & Rapid Capital Appreciation - earlytimes.in
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $7 - 富途牛牛
Wedbush Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Anaphylaxis drives Larimar’s setback, weak efficacy behind MoonLake’s: Clinical Report - BioCentury
Navigating Larimar’s Anaphylaxis Storm: Robust FA Data Presents Risk-Reward Opportunity (NASDAQ:LRMR) - Seeking Alpha
LRMR Analyst Rating Update: Price Target Lowered by Wedbush | LR - GuruFocus
Larimar Therapeutics (NASDAQ:LRMR) Given New $11.00 Price Target at Wedbush - MarketBeat
LRMR: Baird Maintains Rating but Lowers Price Target to $7.00 | - GuruFocus
Wedbush Cuts Price Target on Larimar Therapeutics to $11 From $15, Keeps Outperform Rating - MarketScreener
Baird Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Larimar Therapeutics stock price target lowered to $7 at Jones Trading - Investing.com Canada
Larimar Proceeding Toward Accelerated Approval Filing In Friedreich’s Ataxia - insights.citeline.com
Larimar Therapeutics Inc (LRMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.09%
자본화:
|
볼륨(24시간):